29 March 2023
Latham & Watkins Advises Sonoma Biotherapeutics in Collaboration with Regeneron Pharmaceuticals
Advising firms
Deal team
8 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Judith Hasko Lead | Latham & Watkins LLP | Partner | licensing | Bay Area |
| Mark Roeder Lead | Latham & Watkins LLP | Partner | corporate | Not stated |
| Robert Yeh | Latham & Watkins LLP | Associate | licensing | Not stated |
| Kristina Funahashi | Latham & Watkins LLP | Associate | licensing | Not stated |
| Xiaohan Wu | Latham & Watkins LLP | Associate | licensing | Not stated |
| Michelle Chern | Latham & Watkins LLP | Associate | corporate | Not stated |
| Kirt Switzer | Latham & Watkins LLP | Partner | tax | Not stated |
| Heather Deixler | Latham & Watkins LLP | Partner | data privacy | Not stated |
5 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- Not stated
- What the figure measures
- Not stated
- Client
- Sonoma Biotherapeutics, Inc.Joint venture party
- Counterparties
- Regeneron Pharmaceuticals, Inc. (Joint venture party)